Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PN-associated cholestasis
NCT02334293Unknown
- Sponsor
- Carle Foundation Hospital
- Start
- Oct 2013
- Primary completion
- Jul 2017
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by Carle Foundation Hospital. Primary endpoint: Time from baseline until the patient normalizes bilirubin. Status: unknown.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT02334293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334293.